| 摘要: |
| ［摘要］ 目的 探讨阿德福韦酯联合聚乙二醇干扰素α-2a治疗HBeAg低效价慢性乙型肝炎的疗效。方法 选择2013-02～2015-02该院收治的HBeAg低效价慢性乙型肝炎患者168例，按照随机对照表法分为观察组和对照组各84例，对照组单纯给予阿德福韦酯治疗，观察组在此基础上联合聚乙二醇干扰素α-2a治疗，均治疗48周。观察比较两组临床疗效和用药安全性。结果 观察组HBeAg转阴率和HBeAg血清学转换率分别为78.6%和59.5%，显著高于对照组的56.0%和20.2%，P均<0.05。治疗后两组肝组织HBV-DNA载量均低于治疗前（P<0.05），但两组比较差异无统计学意义（P>0.05）。观察组治疗后HBeAg效价和肝组织HBVcccDNA载量明显低于对照组（P<0.05）。结论 阿德福韦酯联合聚乙二醇干扰素α-2a治疗HBeAg低效价慢性乙型肝炎的临床疗效确切，可有效改善病毒学及血清学应答，但仍需进一步探讨。 |
| 关键词: 阿德福韦酯 聚乙二醇干扰素α-2a HBeAg低效价 慢性乙型肝炎 |
| DOI：10.3969/j.issn.1674-3806.2017.06.16 |
| 分类号:R 512.6+2 |
| 基金项目: |
|
| The curative effect of adefovir dipivoxil combined with pegylated interferon α-2a on treatment of chronic hepatitis B in HBeAg low potency |
|
ZHAI Xing-ju
|
|
Department of Infectious Diseases, the People′s Hospital of Gongyi City, Henan 451200, China
|
| Abstract: |
| ［Abstract］ Objective To observe the curative effect of adefovir dipivoxil combined with pegylated interferon α-2a on the treatment of chronic hepatitis B in HBeAg low potency.Methods The control group(n=84) was treated with adefovir dipivoxil, and the observation group(n=84) was treated with adefovir dipivoxil combined with pegylated interferon alpha-2a. All the patients were treated for 48 weeks and the clinical curative effect and safety were compared between the two groups.Results In the observation group, the negative rates of HBeAg and serum HBeAg were 78.6% and 59.5%, which were significantly higher than those in the control group（56.0% and 20.2%）(P<0.05). In both of the two groups, HBV-DNA loads was significantly lower after the treatment than that before the treatment(P<0.05), but there were no significant difference between the two groups after the treatment(P>0.05). The HBeAg titer and hepatic tissue HBVcccDNA load were significantly lower in the observation group than those in the control group(P<0.05).Conclusion Adefovir dipivoxil combined with pegylated interferon α-2a is effective in the treatment of chronic hepatitis B in HBeAg low potency. |
| Key words: Adefovir dipivoxil Pegylated interferon α-2a HBeAg low potency Chronic hepatitis B |
